CAS 743461-65-6

Carbamic acid, N-[1,1′-biphenyl]-2-yl-, 1-[3-[[2-chloro-4-[[[(2R)-2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]methyl]-5-methoxyphenyl]amino]-3-oxopropyl]-4-piperidinyl ester

CAS : 743461-65-6

Formule : C₄₀H₄₂ClN₅O₇

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 740.2438

Ref: IN-DA00FFPT

Batefenterol

CAS : 743461-65-6

Batefenterol

Degré de pureté : ≥95%

Masse moléculaire : 740.24g/mol

Ref: 54-BUP03419

Batefenterol

CAS : 743461-65-6

Batefenterol (GSK961081) is a muscarinic antagonist and β2-agonist with high affinity (Ki: 1.4/1.3/3.7 nM).

Formule : C₄₀H₄₂ClN₅O₇

Degré de pureté : 97.94% - 98.4%

Couleur et forme : Solid

Masse moléculaire : 740.24

Ref: TM-T7079

Batefenterol

CAS : 743461-65-6

Batefenterol is a pharmaceutical dosage form that is intended to be administered by oral, intravenous, or intramuscular injection. It has been shown to have pharmacodynamic effects on the cardiovascular system. Batefenterol binds to the beta-adrenergic receptor and inhibits the release of catecholamines from the adrenal gland, leading to a decrease in heart rate and blood pressure. The drug also has been shown to increase urine flow and urine volume in patients with benign prostatic hyperplasia. This drug has been shown to be safe for use in vivo models and toxicity studies. Batefenterol is not expected to cause any adverse effects on the central nervous system or liver function tests.

Formule : C₄₀H₄₂ClN₅O₇

Degré de pureté : Min. 95%

Masse moléculaire : 740.24 g/mol

Ref: 3D-TEB46165